· Published by Health Canada · Official notice
June 30, 2017
For immediate release
OTTAWA – Health Canada is advising health care professionals and Canadians that the Canadian authorized version of NARCAN will transition onto the market by July 5, 2017.
NARCAN is a nasal spray form of naloxone, the life-saving drug that temporarily reverses the effects of an opioid overdose.
Last July, an Interim Order was issued by the Minister of Health. The Interim Order permitted the importation, sale and distribution of NARCAN approved in the United States (U.S.) for a period of one year. In September 2016, after a thorough review, Health Canada authorized the Canadian version of NARCAN to ensure an ongoing domestic supply.
On July 5, 2017, the Interim Order will expire. Product obtained under the Interim Order can continue to be used, but new orders will be for the Canadian authorized NARCAN product. There will be a period of time where both products will be available as transition occurs.
NARCAN is the same product in Canada and the U.S. Minor labelling differences are the only distinctions between the Canadian and American versions of the product.
For both versions of the product, it is important to monitor and respect the expiry dates.
Information for anyone who may need to administer naloxone
For more information on how to obtain the Canadian NARCAN Nasal Spray, contact the manufacturer at:
Report health or safety concerns
To report a side effect to a health product to Health Canada:
Related links:
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.